PTC Therapeutics Inc drugs
4 results
Briumvi (ublituximab)
(ublituximab)PTC Therapeutics Inc
Usage: BRIUMVI is indicated for treating relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Cosela (trilaciclib)
(trilaciclib)PTC Therapeutics Inc
Usage: COSELA is indicated to reduce the incidence of chemotherapy-induced myelosuppression in adults when given before a platinum/etoposide or topotecan regimen for extensive-stage small cell lung cancer (ES-SCLC).
Emflaza (deflazacort)
(deflazacort)PTC Therapeutics Inc
Usage: EMFLAZA is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and older.
Kebilidi (eladocagene exuparvovec-tneq)
(eladocagene exuparvovec-tneq)PTC Therapeutics Inc
Usage: KEBILIDI (eladocagene exuparvovec-tneq) is a gene therapy indicated for treating aromatic L-amino acid decarboxylase (AADC) deficiency in adults and pediatric patients. It received accelerated approval based on improvements in gross motor milestones at 48 weeks post-treatment, pending further confirmation of clinical benefit.